ZyVersa Therapeutics Inc. (ZVSA)
NASDAQ: ZVSA
· Real-Time Price · USD
0.31
-0.24 (-43.53%)
At close: Jul 16, 2025, 3:59 PM
ZyVersa Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -2.26B | -9.41M | -21.33M | -21.83M | -97.58M | -98.3M | -89.56M | -90.35M | -13.84M | -14.05M | -11.41M | -9.6M | -9.69M | -8.08M | -6.12M | -4.24M | -2.14M |
Depreciation & Amortization | 6.92M | 6.93M | 6.95M | 18.24K | 18.24K | 10.4K | 9.87K | 9.87K | 9.87K | 9.87K | 10.4K | 10.4K | 10.4K | 10.4K | 7.8K | 5.2K | 2.6K |
Stock-Based Compensation | 330.05M | 257.99M | 258.12M | 924K | 1.13M | 1.19M | 1.29M | 1.54M | 1.87M | 3.52M | 3.95M | 4.86M | 4.16M | 2.22M | 1.4M | 1.92K | 896.23 |
Other Working Capital | 1.14M | 179.31K | -602.17K | -460.85K | -98.73K | 194.51K | 1.48M | 1.87M | 1.08M | 1.67M | 1.42M | 262.8K | -23.38K | -708.45K | -814.36K | -984.28K | -754.32K |
Other Non-Cash Items | -3.35B | -3.35B | -3.34B | 12.9M | 95.86M | 95.25M | 84.02M | 84.22M | 1.23M | 1.47M | 525.99K | 381.74K | 1.87M | 2.94M | 2.88M | 2.79M | 1.34M |
Deferred Income Tax | 9.71M | 9.71M | 9.12M | -586.85K | -8.43M | -9.48M | -9.63M | -9.63M | -1.79M | -745.05K | -12.2K | -472.19K | -472.19K | -472.19K | -459.99K | n/a | n/a |
Change in Working Capital | 2.19M | 929.88K | -391.95K | -288.38K | 1.65M | 2.6M | 7.52M | 8.4M | 6.82M | 8.29M | 5.24M | 2.82M | 1.25M | -1.02M | -1.5M | -1.65M | -1.11M |
Operating Cash Flow | -4.85B | -3.09B | -3.09B | -9.41M | -7.91M | -8.72M | -6.35M | -5.8M | -5.71M | -1.49M | -1.69M | -2M | -3.19M | -5.08M | -4.46M | -3.76M | -2.26M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -75.75M | -75.75M | -75.75M | -75.75M | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | 2.7M | 2.7M | 2.7M | n/a | -2.7M | -2.7M | -2.7M | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | 2.7M | 2.7M | 2.7M | n/a | -78.45M | -78.45M | -78.45M | -75.75M | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | -230K | -10.7M | -10.7M | -10.7M | -10.47M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 4.7B | 2.93B | 2.93B | 2.44M | 1.79M | -912.4K | 253.82K | -497.15K | 441.01K | 868.98K | -4.87M | -4.6M | -4.15M | 686.76K | 5.92M | 5.98M | 5.23M |
Financial Cash Flow | 4.78B | 2.93B | 2.93B | 9.31M | 8.66M | 5.96M | 1.61M | -675.26K | -33.2K | 1.87K | 76.42M | 76.36M | 77.11M | 82.34M | 5.92M | 5.98M | 5.23M |
Net Cash Flow | 3.06B | 2.98B | 2.98B | -109.21K | 755.5K | -2.76M | -4.23M | -5.3M | -4.27M | 370.74K | -342.02K | -1.31M | -1.3M | 1.65M | 2.27M | 2.97M | 2.97M |
Free Cash Flow | -4.85B | -3.09B | -3.09B | -9.41M | -7.91M | -8.72M | -6.35M | -5.8M | -5.71M | -1.49M | -1.69M | -2M | -3.19M | -5.08M | -4.46M | -3.76M | -2.26M |